Press Releases

Press Releases

  • February 15, 2024
    Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
  • February 1, 2024
    Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
  • October 31, 2023
    Aileron Therapeutics Announces Acquisition of Lung Therapeutics
  • February 21, 2023
    Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
  • November 30, 2022
    Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
  • November 10, 2022
    Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
  • November 1, 2022
    Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
  • October 26, 2022
    Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
  • September 30, 2022
    Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
  • September 22, 2022
    Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference